Skip to content

Real-world efficacy and safety evaluation of Danhong injection in the treatment of cerebral infarction/myocardial infarction

Real-world efficacy and safety evaluation of Danhong injection in the treatment of cerebral infarction/myocardial infarction

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400079391
Enrollment
Unknown
Registered
2024-01-02
Start date
2024-02-01
Completion date
Unknown
Last updated
2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute cerebral infarction, acute myocardial infarction

Interventions

Research one: Danhong group:None
Research one: Control group:None
Research two: Danhong group:None
Research two: Control group:None

Sponsors

The Second Affiliated Hospital of Zhejiang Chinese Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to No maximum

Inclusion criteria

Inclusion criteria: Research one: (1) The main diagnosis was acute cerebral infarction, and the course of disease = 2 weeks; (2) Age =40 years old; (3) Complete clinical information; (4) Patients received Danhong injection for = 7 days during hospitalization, or did not receive Danhong injection treatment; (5) Patients with informed consent and agreed to follow-up. Research two: (1) The main diagnosis was acute myocardial infarction; (2) Age =40 years old; (3) Complete clinical information; (4) Patients received Danhong injection for = 7 days during hospitalization, or did not receive Danhong injection treatment; (5) Patients with informed consent and agreed to follow-up.

Exclusion criteria

Exclusion criteria: Research one: (1) Those whose medical history records are not detailed and cannot be extracted; (2) Patients who were lost to follow-up or refused to follow up, or any factor affected the collection of study data. Research two: (1) Those whose medical history records are not detailed and cannot be extracted; (2) Patients who were lost to follow-up or refused to follow up, or any factor affected the collection of study data.

Design outcomes

Primary

MeasureTime frame
Research one: Vascular adverse events within 6 months;Research two: Vascular adverse events within 6 months;

Secondary

MeasureTime frame
Research one: NIHSS score;Research one: mRS Score;Research one: Complications (during hospitalization);Research two: Killip classification;Research two: In-hospital major adverse cardiovascular events;

Countries

China

Contacts

Public ContactBin Xu

The Second Affiliated Hospital of Zhejiang Chinese Medical University

whtong@126.com+86 136 0661 4920

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026